Evaluation of Nelfinavir and Chemoradiation for Pancreatic Cancer
|ClinicalTrials.gov Identifier: NCT01086332|
Recruitment Status : Terminated (Toxicities, lack of funding)
First Posted : March 15, 2010
Last Update Posted : January 8, 2018
University of Iowa
Holden Comprehensive Cancer Center
Information provided by (Responsible Party):
Bryan Allen, University of Iowa
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Terminated|
|Actual Primary Completion Date :||July 2011|
|Actual Study Completion Date :||July 2015|
Plastaras JP, Vapiwala N, Ahmed MS, Gudonis D, Cerniglia GJ, Feldman MD, Frank I, Gupta AK. Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther. 2008 May;7(5):628-35. Epub 2008 May 14.
Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia. 2007 Apr;9(4):271-8.
Pore N, Gupta AK, Cerniglia GJ, Jiang Z, Bernhard EJ, Evans SM, Koch CJ, Hahn SM, Maity A. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res. 2006 Sep 15;66(18):9252-9.